Sandoz officially recognized by Top Employers Institute for its exceptional employee offerings globallyPeople-first policies such as global equal parental leave for 14 weeks and joining the Equal Pay International Coalition contributed to recognitionSe…
Full year net sales for continuing operations1 up 9% (cc2, +6% USD):Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 billion (+71% cc) and Zolgensma USD 361 million Oncology BU growing 10% (cc) driven b…
Full year net sales for continuing operations1 up 9% (cc2, +6% USD):Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 billion (+71% cc) and Zolgensma USD 361 million Oncology BU growing 10% (cc) driven b…
Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting US analysis of long-term financial impact when switching to biosimilar etanercept also presented, modelin…
Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting US analysis of long-term financial impact when switching to biosimilar etanercept also presented, modelin…
Planned acquisition reinforces Sandoz strategic focus on JapanAspen portfolio in Japan consists primarily of off-patent branded medicines with focus on anesthetics and specialty brandsMedicines complement Sandoz broad hospital portfolio and pipeline in…
Planned acquisition reinforces Sandoz strategic focus on JapanAspen portfolio in Japan consists primarily of off-patent branded medicines with focus on anesthetics and specialty brandsMedicines complement Sandoz broad hospital portfolio and pipeline in…
Ziextenzo™ is indicated to decrease the incidence of febrile neutropenia, one of the most serious side effects of chemotherapy With approval of Ziextenzo™ , Sandoz is first and only company to offer US physicians long- and short-acting filgrastim biosi…
Ziextenzo™ is indicated to decrease the incidence of febrile neutropenia, one of the most serious side effects of chemotherapy With approval of Ziextenzo™ , Sandoz is first and only company to offer US physicians long- and short-acting filgrastim biosi…
Continuing operations2 net sales up 13% (cc1, +10% USD) driven by:Cosentyx sales of USD 937 million (+27% cc), with strong demand across indications and regionsEntresto USD 430 million (+61% cc), with increased demand in hospital and ambulatory setting…